Literature DB >> 5152029

Daunorubicin metabolism: estimation of daunorubicin reductase.

N R Bachur, D H Huffman.   

Abstract

1. Daunorubicin reductase, an enzyme ubiquitous in all mammalian tissues tested, converts daunorubicin, a cancer chemotherapeutic antibiotic, to daunorubicinol. A method for the estimation of daunorubicinol and daunorubicin reductase is described.2. Daunorubicin and daunorubicinol were quantitatively extracted from enzyme assay mixtures with 0.3 N HCl in 50% ethanol and then completely hydrolysed to their respective aglycones. The aglycones were extracted, concentrated into toluene, separated by silicic acid microcolumn chromatography, and estimated by spectrofluorimetry.3. Compared to previous methods, this method is highly reproducible and sensitive.

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5152029      PMCID： PMC1665705          DOI： 10.1111/j.1476-5381.1971.tb07219.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  7 in total

1.  FATTY ACID AMIDES OF ETHANOLAMINE IN MAMMALIAN TISSUES.

Authors:  N R BACHUR; K MASEK; K L MELMON; S UDENFRIEND
Journal:  J Biol Chem       Date:  1965-03       Impact factor: 5.157

2.  Daunorubicin metabolism by rat tissue preparations.

Authors:  N R Bachur; M Gee
Journal:  J Pharmacol Exp Ther       Date:  1971-06       Impact factor: 4.030

3.  Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods.

Authors:  N R Bachur; A L Moore; J G Bernstein; A Liu
Journal:  Cancer Chemother Rep       Date:  1970-04

4.  Daunomycin metabolism in rat tissue slices.

Authors:  N R Bachur; J C Cradock
Journal:  J Pharmacol Exp Ther       Date:  1970-11       Impact factor: 4.030

5.  The pharmacokinetics of daunomycin in man.

Authors:  D S Alberts; N R Bachur; J L Holtzman
Journal:  Clin Pharmacol Ther       Date:  1971 Jan-Feb       Impact factor: 6.875

6.  [Trial of treatment of acute lymphoblastic and myeloblastic leukemias by a new antibiotic: rubidomycin (RP 13,057). Study of 61 cases].

Authors:  J Bernard; C Jacquillat; M Boiron; Y Najean; M Seligmann; J Tanzer; M Weil; P Lortholary
Journal:  Presse Med       Date:  1967-04-22       Impact factor: 1.228

7.  Daunorubicinol, a major metabolite of daunorubicin: isolation from human urine and enzymatic reactions.

Authors:  N R Bachur
Journal:  J Pharmacol Exp Ther       Date:  1971-06       Impact factor: 4.030
  7 in total
  4 in total

Review 1.  Mutagenic effects of some anticancer antibiotics.

Authors:  B K Vig
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.

Authors:  Federico Pea; Domenico Russo; Mariagrazia Michieli; Daniela Damiani; Renato Fanin; Angela Michelutti; Teresa Michelutti; Stefano Piccolrovazzi; Michele Baccarani; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Disposition and metabolism of [14-14C] 4-demethoxydaunorubicin HCl (idarubicin) and [14-14C]daunorubicin HCl in the rat. A comparative study.

Authors:  G Zini; G P Vicario; M Lazzati; F Arcamone
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  [The pharmacokinetics of adriamycin and adriamycin-metabolites (author's transl)].

Authors:  G Ehninger; H J Stocker; B Proksch; K Wilms
Journal:  Klin Wochenschr       Date:  1980-09-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.